- Senior consultant; MD
- +47 22 93 44 50
Torbjørn Paulsen studied medicine in Ghent, Belgium 1975-79 and received his medical degree from University of Oslo in 1983, performed his residency in gynecology and obstetrics 1987-83 and become specialist in gynecology and obstetrics in 1993. He defended his thesis “Epithelial ovarian cancer - A clinical epidemiological approach in diagnosis and treatment” in 2007.
In the period 1995 -2000 and from 2008 he has been a senior consultant at the Norwegian Radium Hospital. 2000 – 2008 head of a project on nationally registration of clinical data on ovarian cancer at the Norwegian Cancer Registry. From 2008 he has been head of the Gynecologic Cancer Register in Norway. From 2016 responsible for palliative care at Department for Gynecologic Cancer, Radium Hospital.
Torbjørn Paulsen has been a member of many medical societies, including the European Society of Gynecologic Oncology (ESGO), the International Society of Gynecology Cancer (IGCS), the American Society of Clinical Oncology (ASCO), Nordic Society for Gynecologic oncology (NSGO), Norwegian Society for Gynecologic Oncology (NFGO), Norwegian Gynecologic Society (NGF) and Gynkreftforeningen (patient society).
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
Acta Oncol, 57 (8), 1100-1108
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers
Clin Cancer Res, 14 (22), 7569-73
Epithelial ovarian cancer: a clinical epidemiological approach on diagnosis and treatment
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 549, 1 b. (flere pag.)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
[Examination, treatment and follow-up of ovarian cancer in Norway]
Tidsskr Nor Laegeforen, 121 (23), 2696-700
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
[Controversies in surgical treatment of advanced ovarian cancer]
Tidsskr Nor Laegeforen, 120 (7), 824-30
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Eur J Gynaecol Oncol, 19 (6), 524-8